根据最新临床试验数据显示,渤健公司研发的Salanersen药物在治疗过程中展现出积极效果。所有参与试验的患者在接受该药物治疗后,其病情评估指标均出现不同程度的改善。这些改善体现在一个或多个预设的临床终点指标上,且所有数据均以治疗前基线水平作为参照基准。
根据最新临床试验数据显示,渤健公司研发的Salanersen药物在治疗过程中展现出积极效果。所有参与试验的患者在接受该药物治疗后,其病情评估指标均出现不同程度的改善。这些改善体现在一个或多个预设的临床终点指标上,且所有数据均以治疗前基线水平作为参照基准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.